• Helena Florez, Stanislava Mandelikova, Xavier Filella, Ana Monegal, Núria Guañabens, and Pilar Peris.
• Servicio de Reumatología, Unidad de Patología Metabólica Ósea, Hospital Clínic de Barcelona, CIBERehd, IDIBAPS. Universidad de Barcelona, Barcelona, España.
• Med Clin (Barc). 2018 Jul 23; 151 (2): 65-67.

Introduction And ObjectiveFibrous dysplasia (FD) can be associated with the development of hypophosphatemic osteomalacia, caused by the production of FGF-23 by dysplastic bone tissue. This study analysed FGF-23 levels in patients with FD, and their association with disease activity and serum phosphate values.Patients And MethodsTwelve adult patients with FD were included in the study. Clinical history, disease extension and activity and treatments received were reviewed, and the relationship of those values with FGF-23 and serum P levels was analysed.ResultsFGF-23 was elevated in 6/12 patients (50%). Patients with high FGF-23 levels had similar age and disease activity and extension than those who did not. No differences were observed in serum phosphate values between both groups (increased FGF-23: 3.9±0.9 mg/dl vs. decreased FGF-23: 3.5±0.6 mg/dl). In fact, none of the patients with increased FGF-23 had low serum phosphate values.ConclusionAdult FD patients frequently present elevated FGF-23 values with no serum phosphate level repercussion, suggesting an alteration in the processing of this protein in the dysplastic bone tissue for this pathology.Copyright © 2017 Elsevier España, S.L.U. All rights reserved.

29 keywords...

hide…